Fresenius Group Overview

The Health Care Group
Stories
Archive „Stories“
Investors
Contact

Fresenius SE & Co. KGaA

Investor Relations

+49 (0) 6172 608-2485
ir-fre@fresenius.com
Media
- News
- Social Media
- Calendar
- Contacts
- Media Center
Contact

Matthias Link

Senior Vice President Corporate Communications

T: +49 (0) 6172 608-2872
matthias.link@fresenius.com
Careers
Menu
Filter results
- Chapter
- Format
  - Website (0)
  - PDF (0)
Share
- Facebook
- Twitter
- LinkedIn
- Xing
- Google+
- E-Mail
Services
- Deutsch
- Print
- Contact
- RSS

Investors

Fresenius Investment Highlights

Diversified revenue and earnings base with four strong business segments
Leading positions in non-cyclical markets with predictable growth
Industry-leading organic growth in all business segments
Strong earnings performance and cash flow generation
Attractive shareholder returns
Prudent financial management

"We are reporting a good second quarter 2019, with healthy organic growth in all four business segments. Our investments in future growth are moving ahead according to plan, as we further strengthen the foundations for the long-term, successful development of Fresenius. So we are very confident about the second half and the coming years."

(Stephan Sturm, Chairman of the Management Board)

October 29, 2019 | Bad Homburg, Germany

Conference Call Q3 2019, Fresenius

Import (ICS)

News

Brief News
Fresenius Kabi launches Fulvestrant in prefilled syringes in the U.S.

Fulvestrant Injection is now available in the United States in the company’s ready-to-administer prefilled syringes and is the latest addition to Fresenius Kabi’s broad oncology portfolio. The product is the only room temperature stable Fulvestrant Injection currently available in the U.S.

October 07, 2019Fresenius Kabi

Brief News
Fresenius Helios develops system to measure patient safety

Fresenius Helios has developed a new system for measuring patient safety, and is introducing it in all 86 Helios hospitals across Germany. The new system will complement the company’s existing quality management system and combine internationally established patient safety indicators with various indicators that Helios has developed through clinical practice. These include measurements on such indicators as false diagnoses, medication errors and patient falls. When Helios begins reporting the results next year, it will be the first German hospital operator to provide patient safety data that can be compared internationally.

September 18, 2019Fresenius Helios
Brief News
Fresenius Kabi opens research and development center for biosimilars in Switzerland

Fresenius Kabi has opened a new research and development center for biosimilars in Eysins, in the Swiss canton of Vaud. The facility, in which the company invested about €15 million, will strengthen Fresenius Kabi’s capability to develop new biosimilars, particularly in the areas of autoimmune diseases and oncology. A biosimilar is a drug that is “similar” to another, already approved biologic drug. More than 100 employees representing over 20 nationalities work at the Eysins site, and the company plans to expand the workforce in the near future.

September 18, 2019Fresenius Kabi

Brief News
Fresenius SE & Co. KGaA included in Dow Jones Sustainability Index

Fresenius will be included in the Dow Jones Sustainability Index Europe (DJSI Europe) for the first time as from 23 September 2019. The selected companies must demonstrate continuous improvement with regard to sustainability and are assessed by analysts from asset manager RobecoSAM.

September 17, 2019Fresenius
Brief News
2020 DRG inflator for German hospitals set at 3.66%

The price increase for hospital services in Germany has been set at 3.66% for 2020. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.

September 16, 2019Fresenius Helios

Brief News
Fresenius Helios launches digital portal for patients

Fresenius Helios patients in Germany can soon start accessing letters from their doctors, test results and other medical documents over an online platform – the Helios Patients Portal. This new portal can also be used to make appointments. The confidentiality of patient data is assured through the use of two-factor authentification. All 86 of the company’s hospitals, 126 medical care centers and eight prevention centers throughout Germany are being gradually linked to the Helios Patients Portal. The company is also developing a portal for doctors.

September 11, 2019Fresenius Helios
Fresenius Helios acquires two hospitals in Colombia

September 03, 2019Fresenius Helios

Brief News
Fresenius Kabi launches IV Drug in the U.S.

Phenylephrine Hydrochloride Injection is the latest addition to the company´s growing anesthesia and analgesia portfolio.

August 30, 2019Fresenius Kabi
Brief News
Fresenius Vamed completes main university hospital building in Kiel

After four years of construction Fresenius Vamed has completed the new main building at University Hospital Schleswig-Holstein (UKSH) in Kiel. The completion marks the first milestone in the modernization of Germany’s second-largest university hospital, with the main building of the Lübeck location scheduled to open in November. The project includes new construction and the comprehensive renovation of the two university hospital locations, some 80 kilometers (50 miles) apart in Schleswig-Holstein state, and their technical management through 2044. With a total volume of €1.7 billion, the UKSH’s modernization is currently the biggest public-private partnership project in Europe’s healthcare sector.

August 20, 2019Fresenius Vamed

Brief News
Fresenius Helios expands preventive medicine offering

Fresenius Helios has opened a new Helios Prevention Center in Berlin, as the company continues the expansion of its occupational medicine activities into a standalone business area. The modern, 440-square-meter (4,700-square-foot) center in the heart of Germany’s capital offers comprehensive check-ups from a single source. HCP patients are accompanied throughout the check-up by their own personal physician, and do not have to search for the right department for their next test, deal with different contact persons, or face long waiting times. And if a test turns up something requiring medical treatment, the patient has direct access to the Helios healthcare network and an exclusive hotline for making appointments with specialists.

August 05, 2019Fresenius Helios
Fresenius raises Group sales growth guidance after good second quarter

July 30, 2019Fresenius

Brief News
Fresenius Kabi launches IV Drug in the U.S.

Fresenius Kabi launches Levothyroxine Sodium Injection in the U.S. It is the first, and only, pre-mixed solution of this medication currently available in the U.S.

July 08, 2019Fresenius Kabi
Brief News
Fresenius Kabi launches IV Drug in the U.S.

Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is the latest addition to the company´s growing anesthesia and analgesia portfolio.

June 19, 2019Fresenius Kabi

Brief News
Fresenius Kabi launches Neostigmine in prefilled syringes in the U.S.

Neostigmine is now available in the company’s Simplist® ready-to-administer prefilled syringes, expanding the company´s analgesia and anesthesia portfolio.

June 11, 2019Fresenius Kabi
Brief News
S&P upgrades Fresenius to BBB with stable outlook

Standard & Poor’s has revised Fresenius’ corporate credit rating to BBB with a stable outlook from BBB- with a positive outlook. Fresenius is rated investment grade by the three leading rating agencies Standard & Poor’s (BBB/stable), Moody's (Baa3/stable) and Fitch (BBB-/stable).

May 23, 2019Fresenius

Brief News
Fresenius Kabi launches biosimilar adalimumab IDACIO® in Germany

Fresenius Kabi is launching its first biosimilar in Germany following the European Commission (EC) granting marketing authorization for IDACIO® for all indications of the reference medicine in the areas of rheumatology, gastroenterology and dermatology.

May 03, 2019Fresenius Kabi
Fresenius makes solid start to 2019 and confirms Group guidance

May 02, 2019Fresenius

Brief News
Fresenius Kabi launches Glycopyrrolate in prefilled syringes in the U.S.

Glycopyrrolate is now available in the company’s Simplist™ ready-to-administer prefilled syringes, expanding the company´s analgesia and anesthesia portfolio. It is the first FDA-approved manufacturer-supplied ready-to-administer prefilled syringe for this medication in the U.S.

April 30, 2019Fresenius Kabi
Brief News
Fresenius Kabi launches Adenosine in prefilled syringes in the U.S.

Adenosine, a drug used in critical care settings, is now available in the United States in the company’s Simplist™ ready-to-administer prefilled syringes. Fresenius Kabi now offers the broadest portfolio of Adenosine Injection.

April 09, 2019Fresenius Kabi

Brief News
Fresenius Kabi receives European Commission approval for adalimumab biosimilar IDACIO®

The European Commission (EC) granted Fresenius Kabi the marketing authorization for IDACIO®, an adalimumab biosimilar, for all indications of the reference medicine. With this EC approval, IDACIO® is the first approved molecule of the Fresenius Kabi biosimilars portfolio.

April 03, 2019Fresenius Kabi
Brief News
Fresenius Helios and Marburger Bund agree on collective labor agreement

Helios Germany and the doctors' union Marburger Bund have agreed on a collective labor agreement for about 5,400 physicians in 34 Helios hospitals. It applies to the hospitals included in the Helios Group collective labor agreement. With effect from 1 January 2019, the base salary will increase by 2.5 percent. A further increase of 2.5 percent will follow on January 1, 2020. Salaries will thus increase by a total of 5 percent. This is in line with Fresenius Group's expectations.

March 19, 2019Fresenius Helios

Brief News
Fresenius Helios holds topping-out ceremony for new hospital building in Wiesbaden

Fresenius Helios held the topping-out ceremony today for the new main building at Helios HSK hospital in the German city of Wiesbaden, near Frankfurt. The seven-story structure, with almost 100,000 square meters (about 1 million square feet) of floor space, is being erected beside the existing clinic. It will have 22 operating rooms, about 1,000 beds, and a design that significantly reduces distances and waiting times for patients. Helios is investing about €200 million in the new building, while the state of Hesse is contributing €68 million. Completion is scheduled for 2021.

March 15, 2019Fresenius Helios
Fresenius reports 15th consecutive record year – Significant investments into medium-term growth in FY/18 and FY/19 – Healthy medium-term growth targets

February 20, 2019Fresenius

Brief News
Fresenius Kabi launches IV Drug in the U.S.

Methocarbamol Injection is the newest addition to the company´s anesthesia and analgesia portfolio.

February 12, 2019Fresenius Kabi
Brief News
Fresenius Kabi receives positive CHMP opinion for MSB11022, a biosimilar candidate of adalimumab

Fresenius Kabi announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending marketing authorization for MSB11022 a biosimilar candidate of Humira® (adalimumab)*. The European Commission (EC) will now decide on the approval of MSB11022 which is expected in Q2/ 2019.
*Humira^® is a registered trademark of AbbVie Biotechnology Ltd.

February 01, 2019Fresenius Kabi

Brief News
Fresenius Kabi launches IV Drug in the U.S.

Leucovorin Calcium is the newest addition to the company’s large oncology portfolio.

January 29, 2019Fresenius Kabi
Brief News
Fresenius Vamed adds new resort to network in Austria

VAMED Vitality World has taken over operation of a health resort in Austria’s Styria state. Operating under the new name of Spa Resort Styria in the town of Bad Waltersdorf, near Graz, the resort will offer health tourism for adults. Fresenius Vamed is the market leader in Austria, with about 3.2 million annual visitors to the company’s eight thermal spas and health resorts.

January 14, 2019Fresenius Vamed

Fresenius successfully places €1.0 billion in notes

Fresenius today successfully placed notes in two tranches with an aggregate volume of €1.0 billion.
January 10, 2019Fresenius
Brief News
Fresenius wins award for compensatory time account calculator

Fresenius has been awarded the HR Excellence Award 2018 in the Compensation & Benefits category for the global healthcare group’s compensatory time account calculator. This calculator enables employees to quickly and transparently access information on time off that they have banked, options to take leave for continuing education or to care for family members, and possible early retirement. The HR Excellence Awards have been presented by Human Resources Manager magazine since 2012 to recognize outstanding projects in personnel management.

December 14, 2018Fresenius

Brief News
Fresenius Kabi launches Omegaven® in the U.S.

Omegaven® is an intravenous lipid emulsion that provides calories and fatty acids. In the U.S. it is indicated for pediatric patients with parenteral nutrition-associated cholestasis, or PNAC. With Omegaven® Fresenius Kabi provides the first and only FDA-approved fish oil lipid emulsion for this condition.

December 10, 2018Fresenius Kabi

Disclaimer All News

Library

All Financial Reports

Information & Order Service

Stay informed about the latest news and developments at our Group by subscribing to our Investor News and/or to the Fresenius Brief News. These services are free of charge and may be cancelled at any time.

I am a private investor I am an institutional investor

Title *

First name * Please enter your first name.

Last name * Please enter your last name.

Company * Please enter your company.

Department * Please enter your department.

Job function *

Please enter your function.

Street / Number * Please enter your street.

Postal Code / City * Please enter your postal code and city.

Country *

E-mail * Please enter your e-mail address.

Telephone number

All fields marked with * are required.

Please send me via email

Fresenius Brief News German English

Fresenius Investor News German English

Do you have other questions or need any more information?
Please send us a message:

To unsubscribe to these services, please send a brief e-mail to ir-fre@fresenius.com or call +49 (0) 6172 608-2470.

Follow us

The Health Care Group

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com

Contact

Visit us